Kornimate/medical-research-clean huggingface dataset:
fat reduction in the submandibular/submental area

Conditions: Body Fat Disorder

Summary: the purpose of this study is to further evaluate the safety and efficacy of non-invasive reduction of subcutaneous fat in the submental and submandibular area using cryolipolysis.


Eligibility criteria:
inclusion criteria * male or female subjects \> 22 years of age and \< 65 years of age. * submental and submandibular skin fold thickness \> 1cm (measured by caliper). * no weight change exceeding 5% of body weight in the preceding month. * agreement to maintain his/her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study. * subject has signed a written informed consent form. exclusion criteria * skin laxity in the neck or chin area for which reduction in submental and submandibular fat may, in the opinion of the investigator, result in an unacceptable aesthetic result. * prominent platysmal bands at rest which may interfere with assessment of submental fat * evidence of any cause of enlargement in the submental area other than localized subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands. * significant enlargement on the anterior neck that may prevent the proper placement of the applicator e.g. enlarged thyroid glands. * treatment with dermal fillers, radiofrequency or laser procedures, or chemical peels in the neck or chin area (below the mandible) within the past 6 months. * botulinum toxin or other aesthetic drug injections within the neck or chin area (below the mandible) within the past 6 months. * history of facial nerve paresis or paralysis (such as bell's palsy). * history of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) or implant in or adjacent to the area of intended treatment. * history of prior neck surgery, or prior surgery in the area of intended treatment. * current dental infection. * known history of cryoglobulinemia, cold urticaria, cold agglutinin disease or paroxysmal cold hemoglobinuria. * known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. * history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. * currently taking or has taken diet pills or weight control supplements within the past month. * any dermatological conditions, such as scars in the location of the treatment area that may interfere with the treatment or evaluation. * active implanted device such as a pacemaker, defibrillator, or drug delivery system. * pregnant or intending to become pregnant in the next 6 months. * lactating or has been lactating in the past 6 months. * unable or unwilling to comply with the study requirements. * currently enrolled in a clinical study of an unapproved investigational drug or device. * any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
"connected caesarean section": creating a virtual link between mothers and their infants to improve maternal childbirth experience: a pilot trial

Conditions: Post Traumatic Stress Disorder; Childbirth Experience

Summary: one third of mothers rate their childbirth as traumatic. the prevalence of childbirth-related posttraumatic stress disorder (cb-ptsd) is of 4.7% and the prevalence of childbirth-related posttraumatic stress symptoms (cb-ptss) of 12.3%. skin-to-skin contact is a protective factor against cb-ptsd. however, during a caesarean section (cs), skin-to-skin contact is not always feasible and mothers and infants are often separated. in those cases, there is no validated and available solution to substitute this unique protective factor. based on the results observed in studies using virtual reality (vr) and head-mounted displays (hmds) and studies on childbirth experience, we hypothesize that enabling the mother to have a visual and auditory contact with her baby could improve her childbirth experience whilst she and her baby are separated. to facilitate this connection, we will use a 2d 360° camera filming the baby linked securely to a head-mounted device (hmd) that the mother can wear during the end of the surgery.


Eligibility criteria:
inclusion criteria: * women aged 18 years old or older * planned or unplanned cs at ≥ 34 weeks gestation * gave birth to a healthy baby according to pediatric evaluation (apgar score ≥ 7 at 5 minutes) * gave oral consent followed by a written confirmation of consent * skin-to-skin contact is not possible or was prematurely interrupted * speaks french well enough to participate in study assessments * eligibility confirmed by an independent physician for the intervention group * partner gave oral consent to be filmed for the intervention group. exclusion criteria: * has an established intellectual disability or psychotic illness * has photosensitive epilepsy * caesarean section under general anesthesia

Keywords: mother-infant bonding birth satisfaction hmd virtual reality caesarean section
g-csf and erythropoetin in survival of patients with decompensated liver disease

Conditions: Chronic Liver Disease

Summary: study design 50 patients will be enrolled and randomized into patients (group ia) and controls (group i b) investigations: hematology cbc, prothrombin time and inr peripheral smear, retics biochemistry liver function testing, afp kidney function testing etiology of chronic liver disease infectious etiology: total antihbc, anti hcv, hcv rna, hbv dna non infectious etiology: autoimmune markers, copper studies, iron studies, homa ir, fbs etiology of decompensation variceal bleed infection ( blood culture, urine culture, sputum culture, chest xray) surgery drugs alcohol intake ascitic fluid analysis ugi endoscopy imaging usg abdomen with doppler for spleno-portal axis cect- triple phase upper abdomen liver regenerative potential efficacy testing histology ( by transjugular liver biopsy) liver dendritic cells ( cd11c, cd40, cd 54, cd 123, bdca 2 staining) by flow cytometry cd 34+ cells, cd 45+ cells and cd 133+ cells measurement in hepatic venous blood, peripheral blood and liver biopsy by flow cytometry markers of proliferation like ki- 67, proliferating cell nuclear antigen (pcna) in liver biopsy markers of angiogenesis like vegf, v wf in hepatic venous blood measurement of hepatic venous pressure gradient ( hvpg)


Eligibility criteria:
inclusion criteria: * all patients who were known to have cirrhosis of liver with portal hypertension, now decompensated with ascites/ jaundice/ bleed/ he/ hrs exclusion criteria: * age \ 75 years * autoimmune disorders * hcc * sepsis ( any culture positive: blood, urine, any other obvious source of infection: uti, sbp) * multi organ failure * grade 4 he * hiv seropositivity / pregnancy * essential hypertension * patients being taken up for transplant * refusal to participate in the study
evaluation of efficacy and safety of ave5530 in patients with primary hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the present study is aiming at assessing the efficacy and safety of ave5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. the main objective is to evaluate the effects of ave5530 on ldl-c level reduction as adjunct to a controlled diet. the effects of ave5530 on other lipid parameters will be assessed as secondary objectives.

the study will include a 2-week pre-randomization placebo lead-in phase and a double-blind treatment period of at least 12 months and can be variably extended up to approximately 18 months.

Eligibility criteria:
inclusion criteria: * adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy exclusion criteria: * ldl-c levels \> 250 mg/dl (6.48 mmol/l) * triglycerides levels \> 350mg/dl (3.95 mmol/l) * conditions / situations such as: * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels * active liver disease * high estimated risk of coronary heart disease * recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or unstable or severe peripheral artery disease * positive test for hepatitis b surface antigen and/or hepatitis c antibody or known to be human immunodeficient virus (hiv) positive * pregnant or breast-feeding women, * women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the investigational product. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: primary hypercholesterolemia
musculoskeletal ultrasound in asymptomatic hyperuricemia

Conditions: Hyperuricemia

Summary: an observational study to evaluate the prevalence of us changes of gout in the joints and tendons of patients with different degrees of asymptomatic hyperuricemia. the investigators' findings may support the extension of the spectrum of urate disease, and define a subset of patients that may benefit from early urate-lowering therapy.


Eligibility criteria:
inclusion criteria: 1. patients must have at least one serum uric acid level l ≥ 7.0 mg/dl within the last two years without a clinical diagnosis of gout per american college of rheumatology criteria30 (appendix a). 2. patients, of matched gender and age, with normal uric acid levels will serve as controls. exclusion criteria: 1. patients who meet or have met the acr criteria for gout, unable to read english, and/or have terminal illness will not be eligible to participate in the study. 2. patients with a diagnosis of skin psoriasis31, rheumatoid arthritis, or spondyloarthropathies will not be eligible to participate. 3. patients who are on urate-lowering therapy. 4. patients with 1 or 2 total knee replacements.
effect of acetazolamide on right heart function at rest in lowlanders with copd traveling to high altitude

Conditions: Right Heart Function; Chronic Obstructive Pulmonary Disease; Altitude Sickness

Summary: the purpose of this randomized, placebo-controlled double-blind trial is to evaluate the effect of acetazolamide on right heart function at rest in lowlanders with chronic obstructive pulmonary disease (copd) traveling to high altitude (ha) and developing early signs of altitude-illness.

this randomized placebo-controlled, double-blind, parallel-design trial will evaluate effect of acetazolamide on right heart function in lowlanders with chronic obstructive pulmonary disease (copd) travelling to high altitude and developping early symptoms and/or signs of impending altitude-illness. qualifying participants will be randomized 1:1 to acetazolamide or placebo treatment during their further stay of 2 days at 3'100 m.

Eligibility criteria:
inclusion criteria: * men and women, age 35-75 y, living at low altitude (\<800 m). * copd diagnosed according to the global initiative for obstructive lung disease (gold) guidelines, fev1 40-80% predicted, pulse oximetry ≥92%, paco2 \<6 kpa, breathing ambient air at 760 m. * one of the following early signs and/or symptoms of impending altitudeillness identified by self-monitoring during ascent to or stay at 3100 m: * pulse oximetry spo2≤84% * headache or nausea/vomiting or fatigue/weakness or dizziness/lightheadedness of at least moderate intensity exclusion criteria: * copd exacerbation, very severe copd with hypoxemia or hypercapnia at 760 m (see above). * other lung disease, relevant comorbidities (such as uncontrolled cardiovascular disease, i.e., unstable arterial hypertension, coronary artery disease; previous stroke; obesity (body mass index \>35 kg/m2); internal, neurologic, rheumatologic or psychiatric disease; current heavy smoking (\>20 cigarettes per day). * renal failure and/or allergy to sulfonamides. * patients who do not have early signs and/or signs of impending altitudeillness by self-monitoring (as defined above) at 3'100m will not be included.

Keywords: acetazolamide mountain sickness pulmonary hypertension
a study to evaluate the efficacy, safety, and pharmacokinetics of bfkb8488a compared with placebo in participants with non-alcoholic steatohepatitis

Conditions: Non-alcoholic Steatohepatitis

Summary: this study will evaluate the efficacy, safety, and pharmacokinetics of bfkb8488a compared to placebo in participants with non-alcoholic steatohepatitis (nash).


Eligibility criteria:
inclusion criteria * confirmed diagnosis of nash as documented through liver biopsy performed no more than 6 months before randomization, defined according to nash crn criteria along with a nash crn fibrosis score between f2 and f3 * hepatic steatosis on mri (\>= 8% average pdff) prior to randomization exclusion criteria * history of any liver disease other than nash, except for resolved, self-limited illnesses such as hepatitis a or e, and previous hepatitis c * weight gain \> 10% or loss \> 5% within 3 months prior to randomization * history of liver transplantation * current or history of significant alcohol consumption
assessing the impact of calcium channel blockers on cognitive function in the very elderly (ai-cog)

Conditions: Cognitive Ability, General; High Blood Pressure

Summary: older adults are at increased risk of high blood pressure and cognitive decline. high blood pressure itself also increases risk of cognitive decline. a particular type of blood pressure lowering drug (a calcium channel blocker(ccb)) may lower risk of dementia in younger adults but there is no clear evidence of it's impact in those \>=80. it is important that we know whether ccb use impacts on cognitive function in this age group. this study will examine the impact of antihypertensives on change in cognitive function with a particular focus on ccbs.

this study is an observational cohort study examining cognitive change in those participants taking antihypertensives and aged 80 and over and examining cognitive change in participants taking different types of antihypertensive medication.

Eligibility criteria:
inclusion criteria: aged 80 and over receiving pharmacological treatment for hypertension mini mental state exam score \>24 no other condition likely to limit life to less than one year or to prevent the taking of informed consent. exclusion criteria: aged under 80 years not receiving pharmacological treatment for hypertension mini mental state exam score \<25 diagnosed with a condition likely to limit life to less than one year or to prevent the taking of informed consent. presence of a sensory impairment or an existing neuropsychological deficit of sufficient severity to prevent cognitive testing. presence of a condition that will prevent cognitive testing, registered blind, profoundly deaf, suffering from an aphasia.

Keywords: cognitive decline high blood pressure hypertension ageing dementia antihypertensives
kinesiotaping applied to the thumb in rheumatoid hand

Conditions: Rheumatoid Arthritis; Kinesiotape; Hand Deformity

Summary: objective: it was aimed to evaluate the acute effect of kinesiotape taping on pain, function, range of motion and grip strength parameters in patients with rheumatoid arthritis and hand involvement. material and methods: a total of 34 patients, 27 women and 7 men, diagnosed with ra according to the american rheumatism association (acr) criteria were included in our study. all patients were divided into two groups as kinesiotape and control groups, each consisting of 17 patients. subjective pain intensity was evaluated with the visual analog scale, range of motion was evaluated with a goniometer, functional evaluation was evaluated with the grip skill test, hand grip strength was evaluated with a dynamometer, and finger grip strength was evaluated with a pinchmeter. evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. the patients in the kinesiotape group were taped with the mechanical correction method and the patients in the control group were taped with tensionless gluing of the i tape. applications were made on both dominant and nondominant hands.

this study is a double-blind, randomized clinical trial conducted by the non-interventional ethics committee from april 2018 to october 2018 in the rheumatology unit of a university hospital in turkey. the patients were divided in two groups using simple randomization method. there are 17 patients in groups. as the evaluation content; socio-demographic information was recorded. pain assessment was done by participants' subjective pain intensity visual analogue scale, mobility assessment was made by evaluating the range of motion with a goniometer, functional assessment was by grasping skill test, hand grip strength was measured by dynamometer, and finger grip strength was measured by pinchmeter. in our study, the mechanical correction method of taping to the kinesiotape group was used. in rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. sham application was applied to both dominant and nondominant hands in control group patients. sham taping is the bonding of i tape to the 1st finger without tension and does not contain any features. both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.

Eligibility criteria:
inclusion criteria: * diagnosed as level 2-3 rheumatoid arthritis * no change in pharmacological treatment until 1 month before the study exclusion criteria: * presence of acute disease * diagnosis of level 4 rheumatoid arthritis * intra-articular or intramuscular injection application in the previous months * presence of hand-wrist surgery history in the last 6 months * non-rheumatoid hand deformity

Keywords: rheumatoid arthritis kinesiotape grip strength hand function hand deformity
effect of nano hydroxy apatite varnish and potassium nitrate gel on the mih-affected permanent teeth

Conditions: Molar Incisor Hypomineralisation

Summary: this clinical study main goal is to investigate the effectiveness of nano hydroxy apatite crystal varnish and potassium nitrate gel as a non invasive approach in managing mih-affected teeth.

this randomized clinical trial study aims to investigate the effectiveness of nano-hydroxy apatite crystal varnish, and potassium nitrate gel compared to fluoride varnish, in reducing dentin hypersensitivity, improving a child's oral hygiene, and gingival health, oral health-related quality of life, preventing post-eruptive enamel breakdown, and dental caries, along with economic evaluation.

Eligibility criteria:
the research unit of this study will be the mih-affected permanent tooth, in children aged from six to ten years, from either gender. inclusion criteria: participants related criteria: 1. children aged from six to ten years old. 2. medically free children according to the history taken from their parents. 3. children who are categorized as class i or ii according to the american society of anaesthesiologists (asa). 4. children whom their parents accept to comply with the follow-up visits. 5. children who accept, and their guardians, to participate in the study by signing the informed consent. 6. children with no more than four cavitated primary teeth. tooth related criteria: 1. the diagnosis of mih will be done as per the wurzburg concept, 2023 mih diagnostic criteria: the child will be confirmed to have mih if any of the following characteristics are apparent: * affected teeth show a clearly defined opacity at the occlusal and buccal surfaces of a tooth, * defects vary in shape, size, and pattern, * white, cream-colored, or yellow-brown color deviations are recognizable, * defects variably vary in size, * teeth with hypersensitivity are present, * teeth have an atypical restoration, * permanent teeth for (suspected) mih reasons are missing (extractions), * combinations of the above characteristics are present. 1. mih-affected permanent teeth, suffering from dentin hypersensitivity, (mih-tni 3, 4a). 2. positive schiff cold airblasting sensitivity score (score 1, 2, or 3). * exclusion criteria: participants related criteria: 1. children with severe behavioral or emotional disabilities. 2. children who received analgesics within the last 24 hours before the procedure.15 3. patients who are using chlorhexidine-based gels or mouthwashes. tooth related criteria: 1. a tooth with signs and symptoms of irreversible pulpitis. 2. a tooth with signs and symptoms of necrotic pulp. 3. sealing therapy or application of desensitizing agent on the mih teeth within one month before participation in the study. 4. presence of dental caries on the mih-affected permanent tooth. 5. presence of restoration(s) on mih-affected permanent tooth.
pronostic factors of long term outcome in patients with clubfoot treated by the ponseti method

Conditions: Clubfoot

Summary: we aim at finding prognostic factors of long term (after growth) function outcome in patient with clubfoot treated by ponseti method, based on a very complete prospective recording of treatment variables and outcome


Eligibility criteria:
inclusion criteria: * - patients treated by ponseti method for clubfoot- exclusion criteria: * - other malformation associated / congenital
led photomodulation for prevention of post-radiation treatment dermatitis

Conditions: Radiation Dermatitis

Summary: radiation dermatitis is a common side-effect of radiation therapy in cancer patients who frequently can experience redness, pain, crusting, and even ulceration of the skin causing suffering and treatment interruption. a recent retrospective study by deland demonstrated that administering light emitting diode (led) photomodulation after each radiation treatment for breast cancer decreased radiation dermatitis in a majority of patients. led photomodulation is a process by which specific sequences of light are used to regulate or manipulate cell activity without causing heat or damage to the skin. each led treatment is painless and is completed in usually less than one minute. led photomodulation may reduce the suffering associated with radiation treatments, improve cosmetic outcome in radiation fields, and eliminate breaks in radiation treatments which may be required because of severe ulcerating reactions. this study will attempt to replicate the findings of dr. deland's study by randomly assigning at least 40 breast cancer patients to either a treatment group or to a control group. the treatment group will receive led photomodulation treatments before and after each radiation treatment with the gentlewaves select™ handheld high energy 590nm led array using specific sequences of pulses used in other studies; the treatment group will also receive 7 additional treatments over 2 weeks after their radiation treatment course is completed. the control group will receive no led treatment but will use the exact same skin care regimen as the treatment group. in addition to weekly evaluation and grading of skin reactions, subjects will be photographed under standardized conditions weekly and then photographs will be evaluated and graded by blinded dermatologists.


Eligibility criteria:
inclusion criteria: * subjects must have clinically diagnosed breast or head and neck cancer that will be treated with radiation therapy. * subjects must be at least 18 years of age exclusion criteria: * subjects will not be eligible to participate if they are pregnant or lactating. * patients treated with partial breast irradiation techniques, brachytherapy, or other non-standard techniques will not be eligible.

Keywords: dermatitis skin radiation light led photomodulation gentlewaves